Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

A complex interplay between Akt, TSC2 and the two mTOR complexes.

Huang J, Manning BD.

Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22. doi: 10.1042/BST0370217. Review.

2.

The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.

Huang J, Dibble CC, Matsuzaki M, Manning BD.

Mol Cell Biol. 2008 Jun;28(12):4104-15. doi: 10.1128/MCB.00289-08. Epub 2008 Apr 14.

3.

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Huang J, Wu S, Wu CL, Manning BD.

Cancer Res. 2009 Aug 1;69(15):6107-14. doi: 10.1158/0008-5472.CAN-09-0975. Epub 2009 Jul 14.

4.

Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.

Miyazaki M, McCarthy JJ, Esser KA.

FEBS J. 2010 May;277(9):2180-91. doi: 10.1111/j.1742-4658.2010.07635.x.

5.

A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.

Dalle Pezze P, Sonntag AG, Thien A, Prentzell MT, Gödel M, Fischer S, Neumann-Haefelin E, Huber TB, Baumeister R, Shanley DP, Thedieck K.

Sci Signal. 2012 Mar 27;5(217):ra25. doi: 10.1126/scisignal.2002469.

6.

Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.

Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD.

PLoS One. 2009 Jul 10;4(7):e6189. doi: 10.1371/journal.pone.0006189.

7.

Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.

Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL, Luo Y.

Oncogene. 2007 Aug 16;26(38):5655-61. Epub 2007 Mar 5.

PMID:
17334390
8.

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ.

J Clin Invest. 2007 Mar;117(3):730-8. Epub 2007 Feb 8.

9.

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ.

J Clin Invest. 2003 Oct;112(8):1223-33.

10.

Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.

Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DF, Gallacher J, Sampson JR, Shen MH.

Oncogene. 2015 Feb 12;34(7):922-31. doi: 10.1038/onc.2014.17. Epub 2014 Mar 17.

PMID:
24632604
11.

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.

Julien LA, Carriere A, Moreau J, Roux PP.

Mol Cell Biol. 2010 Feb;30(4):908-21. doi: 10.1128/MCB.00601-09. Epub 2009 Dec 7.

12.

cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.

Xie J, Ponuwei GA, Moore CE, Willars GB, Tee AR, Herbert TP.

Cell Signal. 2011 Dec;23(12):1927-35. doi: 10.1016/j.cellsig.2011.06.025. Epub 2011 Jul 6.

13.

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.

Nobukini T, Thomas G.

Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Review.

PMID:
15562827
14.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

15.
16.

RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.

Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA.

J Cell Biochem. 2010 Feb 1;109(2):320-8. doi: 10.1002/jcb.22380.

PMID:
20014066
17.

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Inoki K, Li Y, Zhu T, Wu J, Guan KL.

Nat Cell Biol. 2002 Sep;4(9):648-57.

PMID:
12172553
18.

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.

Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321.

19.

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.

Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N.

J Biol Chem. 2005 Sep 16;280(37):32081-9. Epub 2005 Jul 15.

20.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. Epub 2004 Sep 1.

Supplemental Content

Support Center